Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.

Kurimchak, Alison M; Shelton, Claude; Herrera-Montávez, Carlos; Duncan, Kelly E; Chernoff, Jonathan; Duncan, James S

Kurimchak, Alison M; Shelton, Claude; Herrera-Montávez, Carlos; Duncan, Kelly E; Chernoff, Jonathan; Duncan, James S.

Affiliation

Kurimchak AM; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Shelton C; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Herrera-Montávez C; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Duncan KE; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Chernoff J; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Duncan JS; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. james.duncan2@fccc.edu.

Mol Cancer Res ; 17(8): 1721-1734, 2019 08.

Article in En | MEDLINE | ID: mdl-31043489

Subject(s)

Cell Cycle Proteins/antagonists & inhibitors; Drug Resistance, Neoplasm/drug effects; MAP Kinase Kinase 1/antagonists & inhibitors; Neurofibromin 1/deficiency; Ovarian Neoplasms/drug therapy; Protein Kinase Inhibitors/pharmacology; Transcription Factors/antagonists & inhibitors; Drug Therapy, Combination; Female; Humans; MAP Kinase Signaling System; Ovarian Neoplasms/metabolism; Ovarian Neoplasms/pathology; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors; Signal Transduction; Tumor Cells, Cultured

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Transcription Factors / Cell Cycle Proteins / Drug Resistance, Neoplasm / Neurofibromin 1 / MAP Kinase Kinase 1 / Protein Kinase Inhibitors Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Mol Cancer Res Year: 2019 Document type: Article

Fulltext

XML

PubMed Links

Search on Google